Tarsus Pharmaceuticals (TARS) stock: insider trades, news & valuation
Heavy selling
Close · Oct 9, 2026
$73.16
+1.3% on the day
+3.9% over 12 months
52-week range $56.11 – $90.78
Share price and insider trades
TARS closeInsider buyInsider sale
Bought, 12 months$0
Sold, 12 months$20.0M
Insiders buying0
Insiders selling9
Tarsus Pharmaceuticals insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 9 sold $20.0M of TARS stock on the open market.
Get emailed when insiders cluster-buy stocks like TARS
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
TARS insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $5.2M | 14 |
| Q2 2026 | — | 0 | $2.5M | 6 |
| Q1 2026 | — | 0 | $9.2M | 30 |
| Q4 2025 | — | 0 | $3.1M | 9 |
Valuation, profit and volume
P/E (trailing)n/aSector median —
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day0.8×Last 5 sessions
Insiders' paper profit—On all tracked purchases —
Summary
Over the past 12 months, 0 Tarsus Pharmaceuticals, Inc. insiders reported open-market purchases totaling $0, while 9 insiders reported sales totaling $20.0M. 36 of 59 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 17SEC | William J Phd LinkDirector | Sell Plan | 11,67595,312 held (−11%) | $78.33 | $915K | -6.6% | — |
| Sep 17SEC | William J Phd LinkDirector | Sell Plan | 75994,553 held (−1%) | $79.00 | $60K | -7.4% | — |
| Sep 17SEC | William J Phd LinkDirector | Sell Plan | 6694,487 held (−0%) | $80.01 | $5K | -8.6% | — |
| Sep 9SEC | Bobak R. AzamianCEO, President | Sell Plan | 7,100830,891 held (−1%) | $90.27 | $641K | -19.0% | — |
| Sep 9SEC | Elizabeth Yeu LinChief Medical Officer | Sell Plan | 5,3862,547 held (−68%) | $90.00 | $485K | -18.7% | — |
| Sep 9SEC | Elizabeth Yeu LinChief Medical Officer | Sell Plan | 5,3877,933 held (−40%) | $85.00 | $458K | -13.9% | — |
| Sep 9SEC | Seshadri NeervannanCOO | Sell Plan | 4,56478,532 held (−5%) | $85.00 | $388K | -13.9% | — |
| Sep 9SEC | Bobak R. AzamianCEO, President | Sell Plan | 2,900827,991 held (−0%) | $91.27 | $265K | -19.8% | — |
| Sep 9SEC | Elizabeth Yeu LinChief Medical Officer | Sell Plan | 1,5901,590 held (−50%) | $90.00 | $143K | -18.7% | — |
| Sep 9SEC | Elizabeth Yeu LinChief Medical Officer | Sell Plan | 1,5903,180 held (−33%) | $85.00 | $135K | -13.9% | — |
| Sep 3SEC | Bobak R. AzamianCEO, President | Sell Plan | 10,000837,991 held (−1%) | $80.06 | $801K | -8.6% | — |
| Sep 3SEC | Elizabeth Yeu LinChief Medical Officer | Sell Plan | 5,38713,320 held (−29%) | $80.00 | $431K | -8.6% | — |
| Sep 3SEC | Elizabeth Yeu LinChief Medical Officer | Sell Plan | 4,60118,707 held (−20%) | $73.86 | $340K | -0.9% | — |
| Sep 3SEC | Elizabeth Yeu LinChief Medical Officer | Sell Plan | 1,5904,770 held (−25%) | $80.00 | $127K | -8.6% | — |
| Jun 22SEC | Bobak R. AzamianCEO, President | Sell Plan | 5,418847,991 held (−1%) | $61.81 | $335K | +18.4% | — |
| Jun 22SEC | Bobak R. AzamianCEO, President | Sell Plan | 4,582853,409 held (−1%) | $61.24 | $281K | +19.5% | — |
| Jun 17SEC | Jeffrey S FarrowSee Remarks | Sell | 14,39656,801 held (−20%) | $60.95 | $877K | +20.0% | — |
| Jun 17SEC | William J Phd LinkDirector | Sell Plan | 10,572108,714 held (−9%) | $61.97 | $655K | +18.1% | — |
| Jun 17SEC | Katherine GoodrichDirector | Sell Plan | 2,9542,233 held (−57%) | $62.08 | $183K | +17.8% | — |
| Jun 17SEC | William J Phd LinkDirector | Sell Plan | 1,928106,786 held (−2%) | $62.94 | $121K | +16.2% | — |
| Mar 24SEC | Seshadri NeervannanCOO | Sell Plan | 2,98982,791 held (−3%) | $66.75 | $200K | +9.6% | — |
| Mar 19SEC | Bobak R. AzamianCEO, President | Sell | 11,66745,385 held (−20%) | $68.71 | $802K | +6.5% | — |
| Mar 19SEC | Bobak R. AzamianCEO, President | Sell | 11,96433,421 held (−26%) | $67.00 | $802K | +9.2% | — |
| Mar 19SEC | Bobak R. AzamianCEO, President | Sell | 10,97257,052 held (−16%) | $69.42 | $762K | +5.4% | — |
| Mar 19SEC | Seshadri NeervannanCOO | Sell | 4,58985,780 held (−5%) | $67.00 | $307K | +9.2% | — |
| Mar 19SEC | Aziz MottiwalaChief Commercial Officer | Sell | 4,28670,250 held (−6%) | $69.42 | $298K | +5.4% | — |
| Mar 19SEC | Aziz MottiwalaChief Commercial Officer | Sell | 4,33065,920 held (−6%) | $68.71 | $298K | +6.5% | — |
| Mar 19SEC | Aziz MottiwalaChief Commercial Officer | Sell | 4,44061,480 held (−7%) | $67.00 | $297K | +9.2% | — |
| Mar 19SEC | Bryan WahlGeneral Counsel | Sell | 4,08472,315 held (−5%) | $69.42 | $284K | +5.4% | — |
| Mar 19SEC | Bryan WahlGeneral Counsel | Sell | 4,23163,959 held (−6%) | $67.00 | $283K | +9.2% | — |
| Mar 19SEC | Bryan WahlGeneral Counsel | Sell | 4,12568,190 held (−6%) | $68.71 | $283K | +6.5% | — |
| Mar 19SEC | Dianne C. WhitfieldChief Human Resources Officer | Sell | 4,07139,202 held (−9%) | $68.71 | $280K | +6.5% | — |
| Mar 19SEC | Dianne C. WhitfieldChief Human Resources Officer | Sell | 4,02943,273 held (−9%) | $69.42 | $280K | +5.4% | — |
| Mar 19SEC | Dianne C. WhitfieldChief Human Resources Officer | Sell | 4,17435,028 held (−11%) | $67.00 | $280K | +9.2% | — |
| Mar 19SEC | Seshadri NeervannanCOO | Sell | 3,61090,369 held (−4%) | $68.71 | $248K | +6.5% | — |
| Mar 19SEC | Seshadri NeervannanCOO | Sell | 3,12593,979 held (−3%) | $69.42 | $217K | +5.4% | — |
| Mar 19SEC | Jeffrey S FarrowSee Remarks | Sell | 2,13345,502 held (−4%) | $68.71 | $147K | +6.5% | — |
| Mar 19SEC | Jeffrey S FarrowSee Remarks | Sell | 2,11147,635 held (−4%) | $69.42 | $147K | +5.4% | — |
| Mar 19SEC | Jeffrey S FarrowSee Remarks | Sell | 2,18643,316 held (−5%) | $67.00 | $146K | +9.2% | — |
| Mar 19SEC | Elizabeth Yeu LinChief Medical Officer | Sell | 39023,308 held (−2%) | $67.00 | $26K | +9.2% | — |
| Mar 19SEC | Elizabeth Yeu LinChief Medical Officer | Sell | 37923,698 held (−2%) | $68.71 | $26K | +6.5% | — |
| Mar 19SEC | Elizabeth Yeu LinChief Medical Officer | Sell | 37524,077 held (−2%) | $69.42 | $26K | +5.4% | — |
| Mar 18SEC | William J Phd LinkDirector | Sell Plan | 8,378116,825 held (−7%) | $69.03 | $578K | +6.0% | — |
| Mar 18SEC | William J Phd LinkDirector | Sell Plan | 3,629125,203 held (−3%) | $68.09 | $247K | +7.4% | — |
| Mar 18SEC | William J Phd LinkDirector | Sell Plan | 493116,332 held (−0%) | $69.75 | $34K | +4.9% | — |
| Mar 5SEC | Seshadri NeervannanCOO | Sell Plan | 8,36670,817 held (−11%) | $76.67 | $641K | -4.6% | — |
| Jan 6SEC | Dianne C. WhitfieldChief Human Resources Officer | Sell Plan | 8,12225,121 held (−24%) | $80.71 | $656K | -9.4% | — |
| Jan 6SEC | Dianne C. WhitfieldChief Human Resources Officer | Sell Plan | 5,71533,243 held (−15%) | $80.09 | $458K | -8.7% | — |
| Jan 6SEC | Dianne C. WhitfieldChief Human Resources Officer | Sell Plan | 89323,393 held (−4%) | $82.93 | $74K | -11.8% | — |
| Jan 6SEC | Dianne C. WhitfieldChief Human Resources Officer | Sell Plan | 83524,286 held (−3%) | $81.90 | $68K | -10.7% | — |
| Dec 30SEC | Bobak R. AzamianCEO, President | Sell Plan | 5,443858,548 held (−1%) | $82.41 | $449K | -11.2% | — |
| Dec 30SEC | Bobak R. AzamianCEO, President | Sell Plan | 557857,991 held (−0%) | $83.54 | $47K | -12.4% | — |
| Dec 18SEC | Dianne C. WhitfieldChief Human Resources Officer | Sell Plan | 7,39738,958 held (−16%) | $80.10 | $592K | -8.7% | — |
| Dec 17SEC | William J Phd LinkDirector | Sell Plan | 6,306129,980 held (−5%) | $81.75 | $516K | -10.5% | — |
| Dec 17SEC | William J Phd LinkDirector | Sell Plan | 5,6804,766 held (−54%) | $80.71 | $458K | -9.4% | — |
| Dec 17SEC | William J Phd LinkDirector | Sell Plan | 5,046136,286 held (−4%) | $80.80 | $408K | -9.5% | — |
| Dec 17SEC | William J Phd LinkDirector | Sell Plan | 4,766 | $81.50 | $388K | -10.2% | — |
| Dec 17SEC | Elizabeth Yeu LinChief Medical Officer | Sell | 2,07821,941 held (−9%) | $79.50 | $165K | -8.0% | — |
| Dec 17SEC | William J Phd LinkDirector | Sell Plan | 1,148128,832 held (−1%) | $82.39 | $95K | -11.2% | — |
Insiders at Tarsus Pharmaceuticals, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Bobak R. AzamianCEO, President | — | $5.2M | Sep 9, 2026 | — |
| William J Phd LinkDirector | — | $4.5M | Sep 17, 2026 | — |
| Dianne C. WhitfieldChief Human Resources Officer | — | $2.7M | Mar 19, 2026 | — |
| Elizabeth Yeu LinChief Medical Officer | — | $2.4M | Sep 9, 2026 | — |
| Seshadri NeervannanCOO | — | $2.0M | Sep 9, 2026 | — |
| Jeffrey S FarrowSee Remarks | — | $1.3M | Jun 17, 2026 | — |
| Aziz MottiwalaChief Commercial Officer | — | $893K | Mar 19, 2026 | — |
| Bryan WahlGeneral Counsel | — | $850K | Mar 19, 2026 | — |
| Katherine GoodrichDirector | — | $183K | Jun 17, 2026 | — |
TARS stock: common questions
Are Tarsus Pharmaceuticals, Inc. insiders buying TARS stock?
In the past 12 months, 0 insiders reported open-market purchases of TARS worth $0.
Are Tarsus Pharmaceuticals, Inc. insiders selling TARS stock?
9 insiders reported sales worth $20.0M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is TARS's 52-week range?
Over the past year TARS has traded between $56.11 and $90.78. It last closed at $73.16 on Oct 9, 2026.